RetaCalc
Protocol library
SingleInvestigationalPhase 3Moderate confidenceSourced

Enclomiphene

An oral selective oestrogen receptor modulator studied for secondary hypogonadism. It is not a peptide and remains unapproved in major markets.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human Study
Men with secondary hypogonadism

Oral 6.25 mg, 12.5 mg or 25 mg once daily in phase 2 pharmacology studies

Trials compared hormonal endpoints with testosterone gel; these are research arms rather than approved labelling.

View source

Evidence summary

An oral selective oestrogen receptor modulator studied for secondary hypogonadism. It is not a peptide and remains unapproved in major markets.

Protocol basis

The protocol summary reports oral dose arms from controlled endocrine studies and separates hormonal surrogate outcomes from approved treatment guidance.

What remains uncertain

Authorised use, long-term patient-centred benefit, rare harms and the role relative to established care remain unsettled.

Warnings and contraindications

Enclomiphene is an oral small molecule, not an injectable peptide.
Hormone changes require diagnosis and monitoring and do not alone establish clinical benefit.
Fertility, vision, mood and thromboembolic risks need clinician assessment.